* Its exosome-based regenerative aesthetics business is fast growing.
* The IPO process will be initiated and stock trading is expected in 1Q 2021 on KOSDAQ.
SEOUL, South Korea, Aug. 25, 2020 /PRNewswire/ — ExoCoBio Inc. announced that it recently raised $9.3 million in its series C and Pre-IPO funding. For this round, return VCs of K2 Investment Partners, SBI Investment Korea, and Dt & Investment were joined by new comers G.N.Tech/ReeHu Investment and Focus Assets Management. Especially, KNOTUS, No. 1 preclinical efficacy CRO in South Korea, made strategic investment into this exosome industry leader.
BENEV Exosome Regenerative Complex, in collaboration with ExoCoBio and BENEV
Since it was established in 2017, ExoCoBio has raised about $56.3 million accumulatively, maintaining the 4th largest exosome industry leadership in the world.
ExoCoBio has been launching a series of exosome-based aesthetic products which are innovative and brand-new items in regenerative aesthetics industry. Among them, ASCE+™, EXOMAGE™, and CELLTWEET™ are leading brands for skin rejuvenation, skin immune-modulation, and scalp rejuvenation.